The incidence rate of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) increases approximately 10% per decade of life starting at 40 years of age. 1 Increased life expectancy is associated with increased chronic disease, and the number of people over 80 years old is estimated to increase to 19.5 million in 2030. 2 The number of men in the United States with LUTS is estimated to reach 11 million by 2030. 3 The economic costs of treating LUTS is estimated at more than $4 billion per year. 4 With an increase in specific comorbidities of BPH/LUTS, 5, 6 the incidence and progression rates of BPH/LUTS as well as the economic burden are likely to increase.
LUTS due to an enlarged prostate are predominantly treated with 5-alpha reductase inhibitors (5ARI), which reduce total prostate volume ∼20% through apoptosis of androgen-dependent luminal epithelia. This medication must be administered continuously with some undesirable side effects. 7 5ARI treatment only reduces the risk of LUTS progression by 34%, exemplifying the need for personalized therapy. 8 Developing precision medicines will require a deeper understanding the molecular pathogenesis of specific phenotypes.
Although prostate anatomy is variable across mammalian species, its cellular architecture is consistent. Stratified columnar epithelial glands are composed of a squamous basal cell layer and a secretory luminal cell layer that express distinct transcriptomes. 9 The incidence of basal cell hyperplasia (BCH) in the human prostate ranges from 8% to 10% of autopsy specimens and can be distinguished from basal cell carcinoma (BCC) based on nuclear morphology and proliferation index. 10 The etiology of BCH is unclear. However, the observation that BCH is associated with chronic lymphocytic inflammation could suggest an initiating event. 11 The normal prostate is an immunocompetent organ that contains small numbers of resident T and B lymphocytes. 12 Chronic inflammation is associated with higher prostate volume, higher risk of urinary retention, and higher risk of symptomatic progression, [13] [14] [15] leading some to propose that BPH is an autoimmune disease. 16 However, inflamed prostates do not uniformly display BCH. Hormones are also purported to play a role in BCH and are intimately linked to inflammation. 17 BCH has also been suggested to increase in response to androgen deprivation 18 and 5ARI therapy, 19 but it is unclear whether this is a primary response to luminal epithelial apoptosis or a secondary response to inflammation downstream of 5ARI treatment.
To gain a clearer understanding of the cellular and molecular pathogenesis of BCH, we performed RNA sequencing on flow cytometry-purified basal epithelia from patients with and without BCH. These data reveal that BCH glands mimic the histomorphological Table 3 . 
| Immunohistochemistry
Dual immunohistochemistry was performed as described previously. 17 Briefly, sections were dewaxed and rehydrated followed by a 20 min block in 3% H 2 O 2 in MeOH. Sections were then subjected to antigen retrieval in boiling citrate solution (pH 6) for 20 min.
Sections were then blocked in 2.5% horse serum for 20 mins at room temperature. Primary antibodies were diluted in 2.5% horse serum and incubated for 60 min at room temperature or overnight at 4°C.
ImmPress-AP Anti-Rabbit (Vector labs, MP-5401) and ImmPress Table 3 .
| RNA-seq analysis
Total RNA from 500 K FACS-purified basal cells was extracted using
RNEasy micro columns (Qiagen). RNA quantity and quality was tested and processed for RNA-Seq on a HiSeq 1500 Sequencer (Illumina) in the UT Southwestern Genomics and Microarray Core.
Sequences (15-20 million) are aligned with HISAT2 21 duplicates are removed using SAMtools 22 and counts are generated using FeatureCount 23 using the annotations from Gencode V20. 24 Genes identified as Globins, rRNAs, and pseudogenes are removed.
Differential expression analysis is performed using edgeR, 25 
| qPCR analysis
For quantitative real-time PCR (qPCR) 50 mg flash-frozen tissue was ground using a mortar and pestle in liquid nitrogen and RNA was extracted with Trizol (Ambion) from 13 non-BCH and 7 BCH specimens. 500 ng RNA was then reverse transcribed into cDNA using RT 2 First Strand Kit (Qiagen, Valencia, CA). qPCR was performed using IQ SYBR Green Supermix (BioRad, Hercules, CA) and results were analyzed using BioRad CFX manager software. All results were calculated using ΔΔCt analysis and normalized to RPL27 expression. Primer sequences are listed in Table 4 .
| Accession numbers
The RNA-seq data on three bulk basal cell epithelial samples from BPH tissues with basal hyperplasia and four bulk basal cell epithelial samples from BPH tissues without basal hyperplasia were deposited into the GEO database (GSE99824). Table 1 ), we were able to detect BCH in 13 specimens, or 9.2% ( Figures 1A vs 1E ). The prevalence of BCH within each specimen was variable, occupying 10-60% of the total area (reviewed by F.F.). Figures 1C vs 1G) . In this regard, it is noteworthy that circulating PSA levels displayed a trending lower mean in BCH versus non-BCH BPH patients, but this may also be because patients with BCH were more likely to be treated with a 5ARI
(69% vs 47%, respectively) ( Table 2) . Finally, previous reports of BCH showed that proliferation is moderate in BCH glands
(1-3%), but significantly higher than in non-BCH glands (0.1%). 10, 39, 40 We performed dual IHC for Ki67 and CK14, but found that Ki67 immunoreactivity in BCH was no different than non-BCH phenotypes ( Figures 1G vs 1H ).
| FACS analysis of primary human BPH tissues confirms expansion of CD49f Hi basal epithelia in patients with BCH
The ratio of basal to luminal epithelia in normal human prostate glands is around 1:1 by histological examination. 41 To compare the ratio of basal to luminal cells in BCH versusn on-BCH, we used a novel tissue phenotyping approach by multicolor flow cytometry. Previous reports identified high expression of cell surface protein CD49f cell as a marker of basal epithelia 42 and CD26 as a marker of luminal epithelia. 43 It is expensive and logistically difficult to prospectively sort out every cell type from each fresh tissue before the histological phenotype is Figure 2C ). 9 These data provided confidence that the basal epithelial cell transcriptomes generated from cryopreserved cells in our BCH patients display high fidelity to the transcriptome of cells before cryopreservation.
It should be noted that the viability of freshly digested cells versus short-(1 week) or long-term (1 year) cryopreserved aliquots is remarkably similar (∼40-50%), but luminal cells are more sensitive to tissue digestion than other cell types (∼30% viability for luminal cells, ∼60% for basal cells, ∼90% for leukocytes, and ∼75% for stroma). 20 This means that only a relative ratio of cell types can be inferred from digested tissue.
One issue with single cell type analyses is the inability to examine a tissue's histological architecture before it is enzymatically digested. The advantage of our study is that most of our biospecimens are large simple prostatectomies that maintain tissue contiguity (unlike the chips of tissue generated by TURP of the prostate, or TURP). Therefore, we could identify patients with a Figure 2D demonstrates that the ratio of basal to luminal cells is significantly higher in tissue with BCH compared to non-BCH tissue, adding confidence to our estimation of BCH by pathology.
We were able to show a statistically significant increase in percent basal epithelia across 21 samples (10 BCH, 11 non-BCH).
Importantly, total CD45 + leukocytes were not significantly different between the two groups ( Figure 2E ). Figure 3B . DAVID analysis 44 revealed several biological pathways related to epidermis and keratinocyte differentiation ( Figure 3C ). GSEA 32 identified several significantly similar DEG sets, with the highest enrichment of an epithelial differentiation module ( Figure 3D ). The enrichment of a curated set of epidermal differentiation complex genes listed in Figure 3E indicated a potential keratinocyte conversion, which we proceeded to confirm by qPCR.
| qPCR confirmation of epidermal differentiation complex gene expression in BCH
Barrier tissues such as the epidermis and esophagus are a stratified epithelium composed of several layers. Basal keratinocytes expressing KRT5/14 (stratum basale) commit to epidermal differentiation by exit from the cell cycle and a supra-basal migration to the spinous, granular, and cornified layers. Each layer is characterized by the expression of genes such as transglutaminases, keratins, cornified envelope precursors, the S100A proteins, and the S100 fused type proteins, which are collectively referred to as the epidermal differentiation complex. 45 In order to confirm the potential for an enrichment of epidermal differentiation complex genes in BCH ( Figure 3E ), we performed qPCR on pieces of whole tissue from 7 patients with BCH and 13 patients without BCH. This was done because limited amounts of RNA can be extracted from sorted cells, and this was used for sequencing. Results show that several of the top differentially expressed epidermal differentiation complex genes were significantly increased in BCH tissues ( Figure 4A-F) . We first examined the expression of several known prostate lineage-specific differentiation markers, which showed a decrease in AR and PSA in BCH specimens as expected ( Figure 4A ). We then systematically examined expression of epidermal differentiation complex genes including keratinocyte keratins ( Figure 4B ), members of the cornified envelope protein (CEP) family ( Figure 4C ), the S100 fused type protein (SFTP) family ( Figure 4D ), the S100A family, and various other keratinocyte markers selected from the significant EDC DEGs shown in Figures 3E and 4E . 
| DISCUSSION
We present a novel approach to characterizing the molecular pathogenesis of a unique BPH phenotype. BPH is an umbrella term that includes a wide range of pathologies including BCH, stromal cell hyperplasia, and glandular hyperplasia. 46 Prostatic basal cell proliferation can range from ordinary BCH to florid BCH and basal cell carcinoma (BCC). Our fresh tissue biorepository specimens did not contain either florid BCH or BCC. The reported incidence of BCH ranges from 8% to 10% 10 . We report here the incidence of BCH in our cohort of 141 BPH patients at 9.2%. Moreover, patients with BCH also display lower local and circulating PSA levels ( Figure 4A and Table 2 ).
A metaplastic differentiation event is commonly observed in response to chronic injury or inflammation such as in Barrett's esophagus where the normal stratified squamous epithelium of the esophagus changes into a columnar epithelium with features of stomach and intestine. 47 In fact, in our DAVID analysis of BCH transcriptomes, the top related tissues were esophagus, keratinocyte, and tongue (data not shown). It has been suggested that BCH is a precursor lesion to BCC given that extensive BCH is observed in patients with BCC. [48] [49] [50] [51] Similar to the links between BCH and BCC, Barrett's esophagus is thought to be a precursor lesion for esophageal cancer. However, the initiating events and the cell of origin (reprogrammed stem cell vs transdifferentiation of terminal cells) are still debated in Barrett's esophagus. 52, 53 Likewise, our understanding of the etiology and pathogenesis of prostatic BCH is unclear.
The association between LUTS progression and chronic infiltration is well-documented. 13, [54] [55] [56] Chronic inflammation is associated with higher prostate volume, higher risk of urinary retention, and higher risk of symptomatic progression in the MTOPS and REDUCE trials. 13, 57 The identification of resident and infiltrating T cells in the prostate has revealed the potential autoimmune nature of BPH, 12, [58] [59] [60] but the molecular links underlying the causes and responses to inflammation are poorly understood. 61 , 62 We did not detect a significant difference in the total number of leukocytes between BPH with BCH versus BPH without BCH ( Figure 2E ). Moreover, it is unclear why the prostate can display high levels of inflammation without BCH if this is a putative initiation event. There is also the possibility that a change in the balance of androgens and estrogens can drive BCH, 18, 19 independent of hormonal effects on inflammation. Sixty-nine percent of our patients with BCH were on 5ARI treatment, but so were 49% of patients in the non-BCH cohort (Table 2) 
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